Biota Pharmaceuticals' CEO Dr. Joseph Patti Interviewed by The Life Sciences Report
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 07/15/15 -- Direct-acting antiviral therapies are poised to become a major disruptive technology in treatment for viruses, including human rhinovirus and human papillomavirus. In , Dr. Joseph M. Patti, CEO of (NASDAQ: BOTA), tells about the novel antiviral therapies in his company's pipeline that address the cause of viral conditions, rather than merely the symptoms.
What's the main differentiator for ?
Biota Pharmaceuticals is focused on infectious diseases. Our core competency is in antivirals. We have three major programs targeting different viruses, using a combination of oral and inhaled drug delivery systems.
What does Biota Pharmaceuticals bring to the antiviral therapy space?
We're going after validated targets that we've seen in the scientific literature. If you have a safe, potent, small molecule that demonstrates good bioavailability at the relevant tissues, you should be able to generate a decent clinical outcome. Thus, for our human rhinovirus (HRV) programs, we're targeting the capsid with vapendavir. Vapendavir binds tightly in the VP1 capsid protein canyon, disrupting the ability of the capsid to bind to a specific cell surface receptor and inhibiting the successful release of the viral RNA into the cell cytoplasm during the viral uncoating process.
Also, there are several incidences in the literature in which potent drugs have yielded beneficial clinical outcomes for respiratory syncytial virus (RSV). For that program, we're targeting...
Continue reading this interview with Dr. Joseph Patti:
Investors rely on to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
Biota Pharmaceuticals Inc. paid The Life Sciences Report to conduct, produce and distribute the interview. Dr. Joseph Patti had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Dr. Joseph Patti and not of The Life Sciences Report or its officers.
Carrie Beal Amaro
Phone: 707-283-0676
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.07.2015 - 13:00 Uhr
Sprache: Deutsch
News-ID 406968
Anzahl Zeichen: 0
contact information:
Town:
SAN FRANCISCO, CA
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 268 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biota Pharmaceuticals' CEO Dr. Joseph Patti Interviewed by The Life Sciences Report"
steht unter der journalistisch-redaktionellen Verantwortung von
Streetwise Reports (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
